FHTX
Foghorn Therapeutics Inc
NASDAQ · Biotechnology
$5.68
+0.45 (+8.60%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 275.09M | 271.86M | 230.16M |
| Net Income | 14.43M | 13.33M | 11.49M |
| EPS | — | — | — |
| Profit Margin | 5.2% | 4.9% | 5.0% |
| Rev Growth | -4.2% | -6.6% | +8.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 171.65M | 139.92M | 178.86M |
| Total Equity | 251.92M | 241.00M | 245.51M |
| D/E Ratio | 0.68 | 0.58 | 0.73 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 18.56M | 20.13M | 16.16M |
| Free Cash Flow | 14.99M | 11.27M | 12.60M |